| Kathryn Irene Musterman, DNP, APRN, AGCNS-BC | |
|
209 Underwood Grove Rd, Cumberland Gap, TN 37724-4609 | |
| (573) 239-1173 | |
| Not Available |
| Full Name | Kathryn Irene Musterman |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 209 Underwood Grove Rd, Cumberland Gap, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083161210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 21555 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Irene Musterman, DNP, APRN, AGCNS-BC 209 Underwood Grove Rd, Cumberland Gap, TN 37724-4609 Ph: (573) 239-1173 | Kathryn Irene Musterman, DNP, APRN, AGCNS-BC 209 Underwood Grove Rd, Cumberland Gap, TN 37724-4609 Ph: (573) 239-1173 |
News Archive
"On Wednesday, July 25, the Global Network for Neglected Tropical Diseases [NTDs] co-chaired a panel at the XIX International AIDS Conference (AIDS 2012), addressing the link between NTDs and HIV/AIDS," the network's "End the Neglect" blog reports.
Physicians, parents and coaches should be cautious when considering treating injured young athletes with platelet rich plasma (PRP), stem cells or other types of regenerative medicine, says a nationally recognized sports medicine clinician and researcher at the University of Miami Miller School of Medicine and UHealth Sports Medicine Institute.
In an essay in The Washington Post, an infectious disease specialist writes that "the unspoken truth among doctors is that we objectively or subjectively ration care, and often don't tell patients or their families."
Ramius V&O Acquisition LLC, a subsidiary of Ramius LLC (collectively, "Ramius"), today announced that it has sent a letter to the Board of Directors of Cypress Bioscience, Inc. outlining its willingness to acquire all of Cypress' outstanding Common Stock in a negotiated transaction for $5.50 per share. The offer is conditioned upon Cypress commencing exclusive negotiations with Ramius no later than Friday, December 10, 2010 and entering into a definitive merger agreement by no later than Sunday, December 12, 2010.
› Verified 3 days ago